tradmap

PLX Protalix BioTherapeutics, Inc.

$2.21 +9.41%

Healthcare · Biological Products, (No Diagnostic Substances)

Protalix BioTherapeutics, Inc. (PLX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $178 million. Shares last traded at $2.21, 30.7% below their 52-week high. Over the past year the stock is up 60.1%. Net profit margin is -12.5%, below the peer median of 6.3%. Revenue declined 1.2% year over year.

Market Cap
$178M
Shares Out
80.6M
EPS (TTM)
$0.12
P/E Ratio
18.42
P/S Ratio
3.38
P/B Ratio
2.65
Dividend / Share
Dividend Yield
52-Week High
$3.19
52-Week Low
$1.32
Volume
135,072
Avg Vol (3m)
53,251.762

Performance

1W
+7.80%
1M
+15.71%
3M
-0.67%
6M
+22.10%
YTD
+26.29%
1Y
+60.14%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
63.12
SMA (50)
$2.09
SMA (200)
$2.17
Price vs SMA50
+5.79%
Price vs SMA200
+1.65%
ATR (14)
$0.08

Financials

Revenue
$53M
Net Income
$-7M
Gross Margin
7.6%
Operating Margin
-10.4%
Net Margin
-12.5%
Return on Equity
-9.8%
Return on Assets
-6.5%
Current Ratio
3.15
Debt / Equity
0.01
Revenue Growth (YoY)
-1.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $0.22 2026-05-13
FY 2025 $-0.08 2026-03-18
Q3 2025 $-0.01 2025-11-13
Q2 2025 $-0.04 2025-08-14
Q1 2026 $-0.05 2026-05-13
FY 2025 $0.04 2026-03-18

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

PLX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
3.38 / 5.21 med
-35% discount
Net margin vs peers
-12.5% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.